| answer text |
<p>The Government has a range of measures in place to support research and development
into novel antimicrobials by small and medium-sized enterprises (SMEs) as part of
our strategy to tackle antimicrobial resistance.</p><p> </p><p>The Department funds
investment of £1 billion annually in the National Institute for Health Research (NIHR).
This includes funding for research infrastructure in the National Health Service which
actively supports collaboration with the life sciences industry and supports the commercialisation
of new research and related technologies to help grow new companies (including SMEs)
and funding. The NIHR also funds the Invention for Innovation (i4i) Programme that
supports collaborative research and development projects in medtech SMEs, universities
and the NHS on the development of innovative medical technologies.</p><p> </p><p>Other
investments that provide opportunities for SMEs include:</p><p><strong> </strong></p><p>-
The £50 million Global AMR Innovation Fund to target investment globally in neglected
and underinvested areas in antimicrobial resistance (AMR) research and development
for the benefit of people in low and middle income countries. The scope includes the
development of novel antimicrobials, including opportunities arising from traditional
Chinese medicine; and</p><p><strong> </strong></p><p>- A call for AMR capital research
proposals for Departmental funding of £4 million delivered by Innovate UK in 2016/17.
The Department plans to invest a further £43 million on a portfolio of AMR capital
research investments over the next three years, subject to appropriate business case
approvals.</p><p><strong> </strong></p>
|
|
